202 related articles for article (PubMed ID: 15941416)
1. Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda.
Sendagire H; Kyabayinze D; Swedberg G; Kironde F
Trop Med Int Health; 2005 Jun; 10(6):537-43. PubMed ID: 15941416
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use.
Nsimba B; Jafari-Guemouri S; Malonga DA; Mouata AM; Kiori J; Louya F; Yocka D; Malanda M; Durand R; Le Bras J
Trop Med Int Health; 2005 Oct; 10(10):1030-7. PubMed ID: 16185238
[TBL] [Abstract][Full Text] [Related]
3. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
Tahar R; Basco LK
Acta Trop; 2007 Aug; 103(2):81-9. PubMed ID: 17640607
[TBL] [Abstract][Full Text] [Related]
4. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
Staedke SG; Sendagire H; Lamola S; Kamya MR; Dorsey G; Rosenthal PJ
Trop Med Int Health; 2004 May; 9(5):624-9. PubMed ID: 15117308
[TBL] [Abstract][Full Text] [Related]
5. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
Mockenhaupt FP; Teun Bousema J; Eggelte TA; Schreiber J; Ehrhardt S; Wassilew N; Otchwemah RN; Sauerwein RW; Bienzle U
Trop Med Int Health; 2005 Sep; 10(9):901-8. PubMed ID: 16135198
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
Happi CT; Gbotosho GO; Folarin OA; Akinboye DO; Yusuf BO; Ebong OO; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
Acta Trop; 2005 Sep; 95(3):183-93. PubMed ID: 16023986
[TBL] [Abstract][Full Text] [Related]
7. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA
Malar J; 2007 Aug; 6():108. PubMed ID: 17686173
[TBL] [Abstract][Full Text] [Related]
8. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.
Talisuna AO; Nalunkuma-Kazibwe A; Langi P; Mutabingwa TK; Watkins WW; Van Marck E; Egwang TG; D'Alessandro U
Infect Genet Evol; 2004 Dec; 4(4):321-7. PubMed ID: 15374529
[TBL] [Abstract][Full Text] [Related]
9. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.
Dorsey G; Dokomajilar C; Kiggundu M; Staedke SG; Kamya MR; Rosenthal PJ
Am J Trop Med Hyg; 2004 Dec; 71(6):758-63. PubMed ID: 15642967
[TBL] [Abstract][Full Text] [Related]
10. Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative.
Sendagire H; Kaddumukasa M; Ndagire D; Aguttu C; Nassejje M; Pettersson M; Swedberg G; Kironde F
Acta Trop; 2005 Sep; 95(3):172-82. PubMed ID: 16018959
[TBL] [Abstract][Full Text] [Related]
11. Point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum and resistance to sulfadoxine-pyrimethamine in Sri Lanka.
Hapuarachchi HC; Dayanath MY; Bandara KB; Abeysundara S; Abeyewickreme W; de Silva NR; Hunt SY; Sibley CH
Am J Trop Med Hyg; 2006 Feb; 74(2):198-204. PubMed ID: 16474070
[TBL] [Abstract][Full Text] [Related]
12. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
Eriksen J; Mwankusye S; Mduma S; Kitua A; Swedberg G; Tomson G; Gustafsson LL; Warsame M
Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):347-53. PubMed ID: 15099990
[TBL] [Abstract][Full Text] [Related]
13. Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
Swarthout TD; van den Broek IV; Kayembe G; Montgomery J; Pota H; Roper C
Trop Med Int Health; 2006 Oct; 11(10):1503-11. PubMed ID: 17002724
[TBL] [Abstract][Full Text] [Related]
14. Associations of antifolate resistance in vitro and point mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum.
Biswas S
J Postgrad Med; 2004; 50(1):17-20. PubMed ID: 15047993
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene].
Djaman AJ; Basco LK; Mazabraud A
Sante; 2002; 12(4):363-7. PubMed ID: 12626289
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo.
Ndounga M; Tahar R; Basco LK; Casimiro PN; Malonga DA; Ntoumi F
Trop Med Int Health; 2007 Oct; 12(10):1164-71. PubMed ID: 17956498
[TBL] [Abstract][Full Text] [Related]
18. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
Kyabayinze D; Cattamanchi A; Kamya MR; Rosenthal PJ; Dorsey G
Am J Trop Med Hyg; 2003 Sep; 69(3):247-52. PubMed ID: 14628939
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré.
Bonnet M; Roper C; Félix M; Coulibaly L; Kankolongo GM; Guthmann JP
Malar J; 2007 May; 6():54. PubMed ID: 17477865
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of chloroquine (CQ) and sulphadoxine/pyrimethamine (SP) therapy in uncomplicated falciparum malaria in Indo-Myanmar border areas.
Mohapatra PK; Prakash A; Taison K; Negmu K; Gohain AC; Namchoom NS; Wange D; Bhattacharyya DR; Goswami BK; Borgohain BK; Mahanta J
Trop Med Int Health; 2005 May; 10(5):478-83. PubMed ID: 15860095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
